<DOC>
	<DOC>NCT02686125</DOC>
	<brief_summary>To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.</brief_summary>
	<brief_title>Registry of Deep Brain Stimulation With the VERCISEâ„¢ System for Treatment of Dystonia: Vercise DBS Dystonia Registry</brief_title>
	<detailed_description>To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia. Subjects' improvement in disease symptoms and overall Quality of life will be assessed.</detailed_description>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<criteria>Inclusion Criteria (IC): IC1. Meets criteria established in the locally applicable Vercise System Directions for Use (DFU) for dystonia. IC2. At least 7 years old. Parent or guardian consent is required in patients who are younger than 18 years at the time of consent. Exclusion Criteria (EC): EC1. Meets any contraindication in the Vercise System locally applicable Directions for Use.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>